- November 14, 2022
- Newsletter
- 617-430-5616
Menu
» Home » CAD » Psychiatry » Adult psychiatry » Bipolar Disorder
ADVERTISEMENT
ADVERTISEMENT
» Home » CAD » Psychiatry » Adult psychiatry » Bipolar Disorder
Background
Epidemiology
Anatomy
Pathophysiology
Etiology
The etiology of bipolar disorder involves a combination of genetic, biological, environmental, and psychosocial factors. While the exact cause is not fully understood, research suggests the following factors contribute to the development of bipolar disorder:
• Genetic Factors: Bipolar disorder has a significant genetic component. Family and twin studies have demonstrated a higher risk of the disorder in individuals with close relatives who have bipolar disorder. Specific genes and genetic variations are being studied better to understand their role in the disorder’s etiology.
• Neurobiological Factors: Imbalances in neurotransmitters, such as serotonin, norepinephrine, and dopamine, are thought to contribute to the etiology of bipolar disorder. Abnormalities in the functioning and regulation of these neurotransmitters can disrupt mood regulation and lead to the characteristic mood swings seen in the disorder.
• Environmental Factors: Stressful events, such as trauma, loss, or significant life changes, may trigger mood episodes. Substance abuse, including alcohol and drug use, can also contribute to developing and exacerbating bipolar disorder. Additionally, disruptions in sleep patterns, social support, and interpersonal relationships may impact the course of the disorder.
• Psychosocial Factors: Psychosocial factors, such as childhood adversity, early life trauma, and dysfunctional family dynamics, increase the risk of developing bipolar disorder. These factors can contribute to the vulnerability and expression of the disorder through their impact on stress response systems, coping mechanisms, and emotional regulation.
Genetics
Prognostic Factors
Clinical History
Non-specific signs & symptoms:
• Mood swings
• Hypomania
• Depression
• Mania
• Irritability
• Impulsiveness
• Loss of interest
• Changes in appetite
• Cognitive impairment
Systemic signs & symptoms
• Fatigue
• Weight disturbances
Physical Examination
When evaluating a patient with suspected bipolar disorder, a comprehensive physical examination is typically conducted to rule out any underlying medical conditions that may contribute to the symptoms or affect treatment decisions. While bipolar disorder primarily involves mood and behavioral symptoms, a physical examination helps assess the patient’s overall health and identify any physical signs that may be relevant. Here are some components of a physical examination that may be performed:
• Vital Signs: Measure blood pressure, heart rate, respiratory rate, and body temperature to assess the patient’s basic physiological parameters.
• General Appearance: Observing the patient’s overall appearance, including their level of distress, hygiene, grooming, and any significant physical abnormalities.
• Neurological Examination: Assessing the patient’s neurological function, including coordination, muscle strength, reflexes, sensation, and cranial nerve examination.
• Cardiovascular Examination: Evaluating the heart and blood vessels, including auscultating the heart sounds, checking for any murmurs or abnormalities, and assessing peripheral pulses.
• Respiratory Examination: Assessing the lungs and respiratory system, including auscultating breath sounds and evaluating the respiratory effort.
• Abdominal Examination: Palpating the abdomen for tenderness, masses, or organ enlargement. Checking for liver or spleen enlargement.
• Skin Examination: Inspect the skin for rashes, lesions, or other dermatological findings relevant to the patient’s health.
• Weight and Body Mass Index (BMI): Measuring the patient’s weight and calculating their BMI to assess any significant weight changes or abnormalities.
Age group
• Children • Adults • Older AdultsAssociated comorbidity
• Substance abuse
• Anxiety disorders
• Attention deficit hyperactivity disorder
• Eating disorders
• Sleep disturbances
• Cardiovascular disease
• Diabetes
Associated activity
Acuity of presentation
Differential Diagnoses
• Major depressive disorder
• Schizophrenia
• Anxiety disorders
• Substance use disorder
• Borderline personality disorder
• Attention deficit hyperactivity disorder in pediatrics
Laboratory Studies
Imaging Studies
Procedures
Histologic Findings
Staging
Treatment Paradigm
by Stage
by Modality
Chemotherapy
Radiation Therapy
Surgical Interventions
Hormone Therapy
Immunotherapy
Hyperthermia
Photodynamic Therapy
Stem Cell Transplant
Targeted Therapy
Palliative Care
Atypical antipsychotic medications, such as aripiprazole, quetiapine, olanzapine, and risperidone, are commonly prescribed in bipolar disorder treatment. They can help manage acute manic or mixed episodes, reduce agitation, stabilize mood, and prevent future episodes. Atypical antipsychotics can be used as monotherapy or in combination with mood stabilizers.
The management of bipolar disorder typically involves several phases, including acute treatment, maintenance treatment, and long-term management. Here’s an overview of these phases:
• Acute treatment phase
• Maintenance phase
• Long-term management
Medication
Monotherapy:
10 mg sublingually every 12 hours a day; may decrease 5 to 10 mg sublingually every 12 hours a day;
Do not exceed 20 mg/day
Adjunctive Therapy:
5 mg sublingually every 12 hours a day; maybe increase to 10 mg sublingually 2 times a day
Do not exceed 20 mg per day
Monotherapy:
10 mg sublingually every 12 hours a day; may decrease 5 to 10 mg sublingually every 12 hours a day;
Do not exceed 20 mg/day
Adjunctive Therapy:
5 mg sublingually every 12 hours a day; maybe increase to 10 mg sublingually 2 times a day
Do not exceed 20 mg per day
Orally
Initial dose:2 to 3mg orally /day
Titration dose: Increase 1mg/day at 24 hours intervals
Maximum dose: 6mg orally /day
Intramuscular
Initial dose:25mg intramuscular every two weeks
Titration dose: may increase up to 37.5mg or 50mg
Maximum dose: 50mg intramuscular every two weeks
Indicated for bipolar mania:
Extended-release capsules:
Initial dose: 200mg orally twice a day
Increase every week by 200mg/dose divided every 6-8 hours
Maximum dose: 1600mg /day
(Depressive Episodes)
The dosage can be titrated upward over four days using either extended-release or immediate-release tablets.
Day 1: 50 mg orally before bed.
Day 2: 100 mg orally before bed.
Day 3: 200 mg orally before bed.
Maintenance (from day 4): 300 mg orally before bed
Dose Adjustments
Mania, Bipolar I Disorder
Given either monotherapy or in the combination with lithium or divalproex.
Immediately release
on day 1: 100 mg orally divided every 12 hours
on day 2: 200 mg orally divided every 12 hours.
on day 3: 300 mg daily orally divided every 12 hours
on day 4: 400 mg daily orally divided every 12 hours
Additional dosage modifications, up to 800 mg daily by day 6, should be given in 200 mg/day increments.
Dosage: 400-800 mg daily, should not exceed more than 800 mg daily
.
Extended release
On Day 1: 300 mg orally once a day
On Day 2: 600 mg orally once a day
Maintenance (after day 3): 400-800 mg daily orally
Maintenance, Bipolar I Disorder
Given in addition to divalproex or lithium
400-800 mg daily orally divided every 12 hours for immediate release
400-800 mg daily orally in a single dose, extended release
In general, patients in the maintenance phase continue to receive the same dose that was used to stabilise them.
Acute treatment: 40 mg orally 2 times a day with meals initially; on day 2, increase to 60-80 mg orally 2 times a day if necessary; modify dose according to tolerability and efficacy within the range of 40-80 mg 2 times a day. Maintenance: Maintain at the same dosage at which the patient was first stabilised; review the necessary for maintenance therapy on a regular basis.
Dose Adjustments
Dosing Modifications Hepatic impairment: Use with caution; the drug is extensively metabolised in the liver, which might increase systemic exposure. Renal impairment: Adjusting the dose is not required with oral administration; caution is necessary with intramuscular administration.
Orally
Initial dose of 15 mg/day orally; may be increased progressively; a maximum daily dose of 30 mg/day.
Adjunct to lithium or valproate:10 to 15 mg/day orally initially; 15 mg/day is the recommended daily dose; may be progressively increased; Do not exceed 30 mg/day.
Continue the stabilization dosage for up to 6 weeks; therapy beyond six weeks has not been investigated.
Abilify Maintena
Patients without prior exposure to aripiprazole should begin with a monthly 400 mg Intramuscular dose.
Only a healthcare expert should administer this medication through deep intramuscular injection into the deltoid or gluteal muscle.
Establish tolerance with aripiprazole orally before beginning Abilify Maintena medication; thoroughly evaluating tolerability may take up to 2 weeks.
In patients with known aripiprazole tolerance, continue aripiprazole orally (10 to 20 mg/day) or other oral antipsychotics for 14 days following the first injection.
Patients who are stable or tolerant to aripiprazole receive 400 mg intramuscularly (IM) once per month. Administer monthly dose no earlier than 26 days after the previous injection. Consider reducing the monthly dose to 300 mg if an adverse reaction occurs.
Abilify Asimtufii (intramuscular every two months)
Never consumed aripiprazole
Establish oral aripiprazole tolerability before initiating 960 mg Intramuscular every two months.
Up to two weeks may be required to assess tolerability in patients with known aripiprazole tolerance thoroughly; continue oral aripiprazole (10 to 20 mg/day) or other antipsychotics Orally for 14 days after the first injection.
Orally antipsychotic-treated
Administer the initial dose of oral aripiprazole along with 10 to 20 mg for 14 consecutive days. Known to tolerate aripiprazole and stable on another oral antipsychotic First injection along with oral antipsychotic medication for 14 consecutive days
Treatment with Abilify Maintena
Administration of Abilify Asimtufii 960 mg every two months instead of the next planned injection of Abilify Maintena (once monthly dose) is recommended for patients on Abilify Maintena. Administer the first injection of Abilify Asimtufii instead of the second or subsequent injection of Abilify Maintena.
If adverse reactions occur with Abilify Asimtufii 960 mg, the dosage may be reduced to 720 mg every two months.
May administer Abilify Asimtufii up to 2 weeks before or after the 2-month timepoint.
levomepromazine (methotrimeprazine)
25 mg 3-4 times intramuscularly each day
Initially, 50-75 mg orally each day divided into 2-3 doses
Increase the dose based on tolerability and response
Patients who take initial high doses should be on bed rest for a few days
A dose of more than 1gm/day may be required in psychotic patients
Indicated for Bipolar Disorder
Extended-release: 900 mg-1800 mg every day orally divided two times a day
Immediate release: 900 mg-1800 mg every day orally divided 3-4 times a day
To reduce adverse drug reactions, decrease the initial dose
Until serum concentration and clinical conditions are balanced, serum lithium levels have to be monitored 12 hrs following the dose, two times a week and every other month afterward
Enhance the dose as tolerated to reach serum lithium Conc. of 0.8-1.2 mEq/lit (i.e., actual goal) or 0.8 mEq/lit -1.0 mEq/lit (i.e., maintenance goal)
Age: 10-17 years
2.5 sublingually every 12 hours a day; may increase to 5 mg sublingually every 12 hours a day after 3 days and to 10 mg sublingually every 12 hours a day after 3 additional days
<10 years: Safety and efficacy not established
>10 years:
Initial dose: 0.5mg/day orally in the morning or evening
Titration dose: may increase 0.5mg to 1mg/day at 24 hours intervals
Maximum dose: 6mg orally per day
10 to 17 years: 2 mg/day orally at first, followed by a rise to 5 mg/day after two days, and then, after an additional two days, to the recommended dosage of 10 mg/day, with consecutive doses potentially increasing by 5 mg/day;
maintenance dose: 10 to 30 mg/day
10 to 17 years: 2 mg/day orally at first, followed by a rise to 5 mg/day after two days, and then, after an additional two days, to the recommended dosage of 10 mg/day, with consecutive doses potentially increasing by 5 mg/day;
maintenance dose: 10 to 30 mg/day
Indicated for Bipolar Disorder as off-label
Age >7 years, body weight <30 kg
300 mg orally two times a day, enhance the dose by 300 mg in a day at weekly intervals depending on tolerability and response; titrate the dose to achieve the serum Conc. of 0.8 mEq/lit -1.2 mEq/lit
Age >7 years, body weight >30 kg
300 mg orally three times a day, the first week of treatment, enhance the dose by 300 mg in a day at weekly intervals depending on tolerability and response; titrate the dose to achieve the serum Conc. of 0.8 mEq/lit -1.2 mEq/lit
Age <7 years
Safety and efficacy not established
Age >12 years
Extended-release tablets:
Body weight <22K.g: 600 mg in a day orally divided two times a day
Body weight 22-41K.g: 900 mg in a day orally divided two times a day
Body weight >41K.g: 1200 mg in a day orally divided two times a day
Enhance the dose as tolerated to reach serum lithium Conc. of 0.8-1.2 mEq/lit (i.e., actual goal) or 0.8 mEq/lit -1.0 mEq/lit (i.e., maintenance goal)
Dose based on weight:
15 mg/kg/dose orally two times a day. It should not exceed 600 mg/dose as an initial dose
Enhance the dose as tolerated to reach serum lithium Conc. of 0.8-1.2 mEq/lit (i.e., actual goal) or 0.8 mEq/lit -1.0 mEq/lit (i.e., maintenance goal
Orally
Initially:0.5mg/day
At an interval of 24 hours, may increase the dose from 1-2mg/day
Maximum dose:16mg orally/day
Intramuscular
Initial dose:25mg intramuscular every two weeks
Titration dose: may increase up to 37.5mg or 50mg
Maximum dose: 50mg intramuscular every two weeks
50-200 mg/day orally for immediate release; can increase to 25-50 mg daily
50 mg/day orally for extended release; may can be increased to 50 mg daily.
Dose Adjustments
Alzheimer's Disease-Related Psychosis and Agitation (Off-label)
12.5-50 mg daily orally at start; increased gradually as tolerated; should not exceed more than 200-300 mg daily
Future Trends
References
• https://www.ncbi.nlm.nih.gov/books/NBK558998/
• https://www.ncbi.nlm.nih.gov/books/NBK547001/
ADVERTISEMENT
» Home » CAD » Psychiatry » Adult psychiatry » Bipolar Disorder
The etiology of bipolar disorder involves a combination of genetic, biological, environmental, and psychosocial factors. While the exact cause is not fully understood, research suggests the following factors contribute to the development of bipolar disorder:
• Genetic Factors: Bipolar disorder has a significant genetic component. Family and twin studies have demonstrated a higher risk of the disorder in individuals with close relatives who have bipolar disorder. Specific genes and genetic variations are being studied better to understand their role in the disorder’s etiology.
• Neurobiological Factors: Imbalances in neurotransmitters, such as serotonin, norepinephrine, and dopamine, are thought to contribute to the etiology of bipolar disorder. Abnormalities in the functioning and regulation of these neurotransmitters can disrupt mood regulation and lead to the characteristic mood swings seen in the disorder.
• Environmental Factors: Stressful events, such as trauma, loss, or significant life changes, may trigger mood episodes. Substance abuse, including alcohol and drug use, can also contribute to developing and exacerbating bipolar disorder. Additionally, disruptions in sleep patterns, social support, and interpersonal relationships may impact the course of the disorder.
• Psychosocial Factors: Psychosocial factors, such as childhood adversity, early life trauma, and dysfunctional family dynamics, increase the risk of developing bipolar disorder. These factors can contribute to the vulnerability and expression of the disorder through their impact on stress response systems, coping mechanisms, and emotional regulation.
Non-specific signs & symptoms:
• Mood swings
• Hypomania
• Depression
• Mania
• Irritability
• Impulsiveness
• Loss of interest
• Changes in appetite
• Cognitive impairment
Systemic signs & symptoms
• Fatigue
• Weight disturbances
When evaluating a patient with suspected bipolar disorder, a comprehensive physical examination is typically conducted to rule out any underlying medical conditions that may contribute to the symptoms or affect treatment decisions. While bipolar disorder primarily involves mood and behavioral symptoms, a physical examination helps assess the patient’s overall health and identify any physical signs that may be relevant. Here are some components of a physical examination that may be performed:
• Vital Signs: Measure blood pressure, heart rate, respiratory rate, and body temperature to assess the patient’s basic physiological parameters.
• General Appearance: Observing the patient’s overall appearance, including their level of distress, hygiene, grooming, and any significant physical abnormalities.
• Neurological Examination: Assessing the patient’s neurological function, including coordination, muscle strength, reflexes, sensation, and cranial nerve examination.
• Cardiovascular Examination: Evaluating the heart and blood vessels, including auscultating the heart sounds, checking for any murmurs or abnormalities, and assessing peripheral pulses.
• Respiratory Examination: Assessing the lungs and respiratory system, including auscultating breath sounds and evaluating the respiratory effort.
• Abdominal Examination: Palpating the abdomen for tenderness, masses, or organ enlargement. Checking for liver or spleen enlargement.
• Skin Examination: Inspect the skin for rashes, lesions, or other dermatological findings relevant to the patient’s health.
• Weight and Body Mass Index (BMI): Measuring the patient’s weight and calculating their BMI to assess any significant weight changes or abnormalities.
• Substance abuse
• Anxiety disorders
• Attention deficit hyperactivity disorder
• Eating disorders
• Sleep disturbances
• Cardiovascular disease
• Diabetes
• Major depressive disorder
• Schizophrenia
• Anxiety disorders
• Substance use disorder
• Borderline personality disorder
• Attention deficit hyperactivity disorder in pediatrics
The management of bipolar disorder typically involves several phases, including acute treatment, maintenance treatment, and long-term management. Here’s an overview of these phases:
• Acute treatment phase
• Maintenance phase
• Long-term management
Monotherapy:
10 mg sublingually every 12 hours a day; may decrease 5 to 10 mg sublingually every 12 hours a day;
Do not exceed 20 mg/day
Adjunctive Therapy:
5 mg sublingually every 12 hours a day; maybe increase to 10 mg sublingually 2 times a day
Do not exceed 20 mg per day
Monotherapy:
10 mg sublingually every 12 hours a day; may decrease 5 to 10 mg sublingually every 12 hours a day;
Do not exceed 20 mg/day
Adjunctive Therapy:
5 mg sublingually every 12 hours a day; maybe increase to 10 mg sublingually 2 times a day
Do not exceed 20 mg per day
Orally
Initial dose:2 to 3mg orally /day
Titration dose: Increase 1mg/day at 24 hours intervals
Maximum dose: 6mg orally /day
Intramuscular
Initial dose:25mg intramuscular every two weeks
Titration dose: may increase up to 37.5mg or 50mg
Maximum dose: 50mg intramuscular every two weeks
Indicated for bipolar mania:
Extended-release capsules:
Initial dose: 200mg orally twice a day
Increase every week by 200mg/dose divided every 6-8 hours
Maximum dose: 1600mg /day
(Depressive Episodes)
The dosage can be titrated upward over four days using either extended-release or immediate-release tablets.
Day 1: 50 mg orally before bed.
Day 2: 100 mg orally before bed.
Day 3: 200 mg orally before bed.
Maintenance (from day 4): 300 mg orally before bed
Dose Adjustments
Mania, Bipolar I Disorder
Given either monotherapy or in the combination with lithium or divalproex.
Immediately release
on day 1: 100 mg orally divided every 12 hours
on day 2: 200 mg orally divided every 12 hours.
on day 3: 300 mg daily orally divided every 12 hours
on day 4: 400 mg daily orally divided every 12 hours
Additional dosage modifications, up to 800 mg daily by day 6, should be given in 200 mg/day increments.
Dosage: 400-800 mg daily, should not exceed more than 800 mg daily
.
Extended release
On Day 1: 300 mg orally once a day
On Day 2: 600 mg orally once a day
Maintenance (after day 3): 400-800 mg daily orally
Maintenance, Bipolar I Disorder
Given in addition to divalproex or lithium
400-800 mg daily orally divided every 12 hours for immediate release
400-800 mg daily orally in a single dose, extended release
In general, patients in the maintenance phase continue to receive the same dose that was used to stabilise them.
Acute treatment: 40 mg orally 2 times a day with meals initially; on day 2, increase to 60-80 mg orally 2 times a day if necessary; modify dose according to tolerability and efficacy within the range of 40-80 mg 2 times a day. Maintenance: Maintain at the same dosage at which the patient was first stabilised; review the necessary for maintenance therapy on a regular basis.
Dose Adjustments
Dosing Modifications Hepatic impairment: Use with caution; the drug is extensively metabolised in the liver, which might increase systemic exposure. Renal impairment: Adjusting the dose is not required with oral administration; caution is necessary with intramuscular administration.
Orally
Initial dose of 15 mg/day orally; may be increased progressively; a maximum daily dose of 30 mg/day.
Adjunct to lithium or valproate:10 to 15 mg/day orally initially; 15 mg/day is the recommended daily dose; may be progressively increased; Do not exceed 30 mg/day.
Continue the stabilization dosage for up to 6 weeks; therapy beyond six weeks has not been investigated.
Abilify Maintena
Patients without prior exposure to aripiprazole should begin with a monthly 400 mg Intramuscular dose.
Only a healthcare expert should administer this medication through deep intramuscular injection into the deltoid or gluteal muscle.
Establish tolerance with aripiprazole orally before beginning Abilify Maintena medication; thoroughly evaluating tolerability may take up to 2 weeks.
In patients with known aripiprazole tolerance, continue aripiprazole orally (10 to 20 mg/day) or other oral antipsychotics for 14 days following the first injection.
Patients who are stable or tolerant to aripiprazole receive 400 mg intramuscularly (IM) once per month. Administer monthly dose no earlier than 26 days after the previous injection. Consider reducing the monthly dose to 300 mg if an adverse reaction occurs.
Abilify Asimtufii (intramuscular every two months)
Never consumed aripiprazole
Establish oral aripiprazole tolerability before initiating 960 mg Intramuscular every two months.
Up to two weeks may be required to assess tolerability in patients with known aripiprazole tolerance thoroughly; continue oral aripiprazole (10 to 20 mg/day) or other antipsychotics Orally for 14 days after the first injection.
Orally antipsychotic-treated
Administer the initial dose of oral aripiprazole along with 10 to 20 mg for 14 consecutive days. Known to tolerate aripiprazole and stable on another oral antipsychotic First injection along with oral antipsychotic medication for 14 consecutive days
Treatment with Abilify Maintena
Administration of Abilify Asimtufii 960 mg every two months instead of the next planned injection of Abilify Maintena (once monthly dose) is recommended for patients on Abilify Maintena. Administer the first injection of Abilify Asimtufii instead of the second or subsequent injection of Abilify Maintena.
If adverse reactions occur with Abilify Asimtufii 960 mg, the dosage may be reduced to 720 mg every two months.
May administer Abilify Asimtufii up to 2 weeks before or after the 2-month timepoint.
levomepromazine (methotrimeprazine)
25 mg 3-4 times intramuscularly each day
Initially, 50-75 mg orally each day divided into 2-3 doses
Increase the dose based on tolerability and response
Patients who take initial high doses should be on bed rest for a few days
A dose of more than 1gm/day may be required in psychotic patients
Indicated for Bipolar Disorder
Extended-release: 900 mg-1800 mg every day orally divided two times a day
Immediate release: 900 mg-1800 mg every day orally divided 3-4 times a day
To reduce adverse drug reactions, decrease the initial dose
Until serum concentration and clinical conditions are balanced, serum lithium levels have to be monitored 12 hrs following the dose, two times a week and every other month afterward
Enhance the dose as tolerated to reach serum lithium Conc. of 0.8-1.2 mEq/lit (i.e., actual goal) or 0.8 mEq/lit -1.0 mEq/lit (i.e., maintenance goal)
Age: 10-17 years
2.5 sublingually every 12 hours a day; may increase to 5 mg sublingually every 12 hours a day after 3 days and to 10 mg sublingually every 12 hours a day after 3 additional days
<10 years: Safety and efficacy not established
>10 years:
Initial dose: 0.5mg/day orally in the morning or evening
Titration dose: may increase 0.5mg to 1mg/day at 24 hours intervals
Maximum dose: 6mg orally per day
10 to 17 years: 2 mg/day orally at first, followed by a rise to 5 mg/day after two days, and then, after an additional two days, to the recommended dosage of 10 mg/day, with consecutive doses potentially increasing by 5 mg/day;
maintenance dose: 10 to 30 mg/day
10 to 17 years: 2 mg/day orally at first, followed by a rise to 5 mg/day after two days, and then, after an additional two days, to the recommended dosage of 10 mg/day, with consecutive doses potentially increasing by 5 mg/day;
maintenance dose: 10 to 30 mg/day
Indicated for Bipolar Disorder as off-label
Age >7 years, body weight <30 kg
300 mg orally two times a day, enhance the dose by 300 mg in a day at weekly intervals depending on tolerability and response; titrate the dose to achieve the serum Conc. of 0.8 mEq/lit -1.2 mEq/lit
Age >7 years, body weight >30 kg
300 mg orally three times a day, the first week of treatment, enhance the dose by 300 mg in a day at weekly intervals depending on tolerability and response; titrate the dose to achieve the serum Conc. of 0.8 mEq/lit -1.2 mEq/lit
Age <7 years
Safety and efficacy not established
Age >12 years
Extended-release tablets:
Body weight <22K.g: 600 mg in a day orally divided two times a day
Body weight 22-41K.g: 900 mg in a day orally divided two times a day
Body weight >41K.g: 1200 mg in a day orally divided two times a day
Enhance the dose as tolerated to reach serum lithium Conc. of 0.8-1.2 mEq/lit (i.e., actual goal) or 0.8 mEq/lit -1.0 mEq/lit (i.e., maintenance goal)
Dose based on weight:
15 mg/kg/dose orally two times a day. It should not exceed 600 mg/dose as an initial dose
Enhance the dose as tolerated to reach serum lithium Conc. of 0.8-1.2 mEq/lit (i.e., actual goal) or 0.8 mEq/lit -1.0 mEq/lit (i.e., maintenance goal
Orally
Initially:0.5mg/day
At an interval of 24 hours, may increase the dose from 1-2mg/day
Maximum dose:16mg orally/day
Intramuscular
Initial dose:25mg intramuscular every two weeks
Titration dose: may increase up to 37.5mg or 50mg
Maximum dose: 50mg intramuscular every two weeks
50-200 mg/day orally for immediate release; can increase to 25-50 mg daily
50 mg/day orally for extended release; may can be increased to 50 mg daily.
Dose Adjustments
Alzheimer's Disease-Related Psychosis and Agitation (Off-label)
12.5-50 mg daily orally at start; increased gradually as tolerated; should not exceed more than 200-300 mg daily
• https://www.ncbi.nlm.nih.gov/books/NBK558998/
• https://www.ncbi.nlm.nih.gov/books/NBK547001/
The etiology of bipolar disorder involves a combination of genetic, biological, environmental, and psychosocial factors. While the exact cause is not fully understood, research suggests the following factors contribute to the development of bipolar disorder:
• Genetic Factors: Bipolar disorder has a significant genetic component. Family and twin studies have demonstrated a higher risk of the disorder in individuals with close relatives who have bipolar disorder. Specific genes and genetic variations are being studied better to understand their role in the disorder’s etiology.
• Neurobiological Factors: Imbalances in neurotransmitters, such as serotonin, norepinephrine, and dopamine, are thought to contribute to the etiology of bipolar disorder. Abnormalities in the functioning and regulation of these neurotransmitters can disrupt mood regulation and lead to the characteristic mood swings seen in the disorder.
• Environmental Factors: Stressful events, such as trauma, loss, or significant life changes, may trigger mood episodes. Substance abuse, including alcohol and drug use, can also contribute to developing and exacerbating bipolar disorder. Additionally, disruptions in sleep patterns, social support, and interpersonal relationships may impact the course of the disorder.
• Psychosocial Factors: Psychosocial factors, such as childhood adversity, early life trauma, and dysfunctional family dynamics, increase the risk of developing bipolar disorder. These factors can contribute to the vulnerability and expression of the disorder through their impact on stress response systems, coping mechanisms, and emotional regulation.
Non-specific signs & symptoms:
• Mood swings
• Hypomania
• Depression
• Mania
• Irritability
• Impulsiveness
• Loss of interest
• Changes in appetite
• Cognitive impairment
Systemic signs & symptoms
• Fatigue
• Weight disturbances
When evaluating a patient with suspected bipolar disorder, a comprehensive physical examination is typically conducted to rule out any underlying medical conditions that may contribute to the symptoms or affect treatment decisions. While bipolar disorder primarily involves mood and behavioral symptoms, a physical examination helps assess the patient’s overall health and identify any physical signs that may be relevant. Here are some components of a physical examination that may be performed:
• Vital Signs: Measure blood pressure, heart rate, respiratory rate, and body temperature to assess the patient’s basic physiological parameters.
• General Appearance: Observing the patient’s overall appearance, including their level of distress, hygiene, grooming, and any significant physical abnormalities.
• Neurological Examination: Assessing the patient’s neurological function, including coordination, muscle strength, reflexes, sensation, and cranial nerve examination.
• Cardiovascular Examination: Evaluating the heart and blood vessels, including auscultating the heart sounds, checking for any murmurs or abnormalities, and assessing peripheral pulses.
• Respiratory Examination: Assessing the lungs and respiratory system, including auscultating breath sounds and evaluating the respiratory effort.
• Abdominal Examination: Palpating the abdomen for tenderness, masses, or organ enlargement. Checking for liver or spleen enlargement.
• Skin Examination: Inspect the skin for rashes, lesions, or other dermatological findings relevant to the patient’s health.
• Weight and Body Mass Index (BMI): Measuring the patient’s weight and calculating their BMI to assess any significant weight changes or abnormalities.
• Substance abuse
• Anxiety disorders
• Attention deficit hyperactivity disorder
• Eating disorders
• Sleep disturbances
• Cardiovascular disease
• Diabetes
• Major depressive disorder
• Schizophrenia
• Anxiety disorders
• Substance use disorder
• Borderline personality disorder
• Attention deficit hyperactivity disorder in pediatrics
Psychiatry/Mental Health
Psychiatry/Mental Health
The management of bipolar disorder typically involves several phases, including acute treatment, maintenance treatment, and long-term management. Here’s an overview of these phases:
• Acute treatment phase
• Maintenance phase
• Long-term management
• https://www.ncbi.nlm.nih.gov/books/NBK558998/
• https://www.ncbi.nlm.nih.gov/books/NBK547001/
Founded in 2014, medtigo is committed to providing high-quality, friendly physicians, transparent pricing, and a focus on building relationships and a lifestyle brand for medical professionals nationwide.
USA – BOSTON
60 Roberts Drive, Suite 313
North Adams, MA 01247
INDIA – PUNE
7, Shree Krishna, 2nd Floor, Opp Kiosk Koffee, Shirole Lane, Off FC Road, Pune 411004, Maharashtra
Founded in 2014, medtigo is committed to providing high-quality, friendly physicians, transparent pricing, and a focus on building relationships and a lifestyle brand for medical professionals nationwide.
MASSACHUSETTS – USA
60 Roberts Drive, Suite 313,
North Adams, MA 01247
MAHARASHTRA – INDIA
7, Shree Krishna, 2nd Floor,
Opp Kiosk Koffee,
Shirole Lane, Off FC Road,
Pune 411004, Maharashtra